Ivermectin B1a

Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310) [1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].

Product Specifications

CAS Number

[71827-03-7]

UNSPSC

12352005

Hazard Statement

H301

Target

Parasite; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ivermectin-b1a.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C([C@H]([C@H](/C=C/C=C1CO[C@]([H])([C@@H](C(C)=C[C@]2(C3=O)[H])O)[C@@]\12O)C)O[C@]4(C[C@@H]([C@H]([C@@H](O4)C)O[C@@]5(O[C@H]([C@@H]([C@H](C5)OC)O)C)[H])OC)[H])=C\C[C@@]6(C[C@@]([H])(C[C@@]7(O6)CC[C@@H]([C@]([H])(O7)[C@@H](C)CC)C)O3)[H]

Molecular Formula

C48H74O14

Molecular Weight

875.09

Precautions

H301

References & Citations

[1]Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo) . 2017 May;70 (5) :680-684.|[2]Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19 (1) :23.